A Phase 1 interventional study of MK 0773 and Placebo in Osteoporosis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-10.
Sponsored by Merck Sharp & Dohme LLC · Phase 1, Interventional, and Treatment
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic efficacy of MK0773 in healthy postmenopausal women.
1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.
This study's enrollment of 67 is below the median of 95 across 1,133 interventional studies indexed under Osteoporosis.
Browse Osteoporosis studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 133 are open to participants now.
Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: MK 0773
Placebo
Drug: Placebo
25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
Placebo oral tablet b.i.d for 12 weeks
Number of Participants with Serious Clinical Adverse Events
Time frame: From date of enrollment through 12 weeks of study
Number of Participants with Nonerserious Clinical Adverse Events
Time frame: From date of enrollment through 12 weeks of study
Number of Participants with Serious Laboratory Adverse Events
Time frame: From date of enrollment through 12 weeks of study
Number of Participants with Nonserious Laboratory Adverse Events
Time frame: From date of enrollment through 12 weeks of study
Number of Participants Who Discontinued Due to Any Adverse Event
Time frame: From date of enrollment through 12 weeks of study
Number of Participants Who Withdrew Consent and Discontinued the Study
Time frame: From date of enrollment through 12 weeks of study
Least Squares Mean Change in Lean Body Mass
Time frame: From baseline, at 12 weeks
No study locations are listed for this record.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck Sharp & Dohme LLC